Lenz Therapeutics vs Scynexis
Lenz Therapeutics and Scynexis are similar in size: $19.1m and $20.6m of revenue in their latest fiscal years. Scynexis kept more of each dollar of sales as profit: a net margin of -41.8% against -430.3%. Lenz Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Lenz TherapeuticsLENZ, 2025 | ScynexisSCYX, 2025 |
|---|---|---|
| Revenue | $19.1m | $20.6m |
| Revenue growth | — | 449.9% |
| Net income | −$82.1m | −$8.6m |
| Operating margin | -477.5% | -78.0% |
| Net margin | -430.3% | -41.8% |
| Return on equity | -33.6% | -16.5% |
| Free cash flow | −$70.0m | −$5.3m |
| Cash | $25.2m | $21.3m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 152 | 18 |
| Market value | $111m | $39.1m |
| Price vs our value range | — | — |
| Moat score | — | 9 (Weak) |
| Insider trades, 12 months | 6 buys, 5 sales | 1 buys, 0 sales |